跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Regulus
首页
药物
Regulus
Regulus
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
申请人: REGULUS THERAPEUTICS INC
优先权: 2004
US
41 件公开
Methods for treatment of alport syndrome
申请人: REGULUS THERAPEUTICS INC
优先权: 2013
US
5 件公开
MicroRNA compounds and methods for modulating MIR-21 activity
申请人: BHAT BALKRISHEN
优先权: 2012
US
6 件公开
MicroRNA compounds and methods for modulating miR-122
申请人: REGULUS THERAPEUTICS INC
优先权: 2014
CN
US
7 件公开
MODIFIED OLIGONUCLEOTIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE
申请人: REGULUS THERAPEUTICS INC
优先权: 2023
CN
EP
WO
3 件公开
METHODS AND COMPOSITIONS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
申请人: REGULUS THERAPEUTICS INC
优先权: 2021
CN
EP
US
WO
7 件公开
COMPOUND FOR USE IN METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
申请人: REGULUS THERAPEUTICS INC
优先权: 2024
WO
MicroRNA compounds and methods for modulating miR-21 activity
申请人: REGULUS THERAPEUTICS INC
优先权: 2013
US
6 件公开
药物
反馈